It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAM’s FA Score shows that 0 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAM’s TA Score shows that 3 TA indicator(s) are bullish.
BEAM (@Biotechnology) experienced а +3.87% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.
BEAM is expected to report earnings on Mar 04, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
BEAM | IBB | |
---|---|---|
RSI ODDS (%) | N/A | 3 days ago90% |
Stochastic ODDS (%) | 3 days ago90% | 3 days ago87% |
Momentum ODDS (%) | 3 days ago83% | 3 days ago88% |
MACD ODDS (%) | 3 days ago84% | 3 days ago88% |
TrendWeek ODDS (%) | 3 days ago82% | 3 days ago87% |
TrendMonth ODDS (%) | 3 days ago83% | 3 days ago88% |
Advances ODDS (%) | 3 days ago81% | 6 days ago87% |
Declines ODDS (%) | 5 days ago85% | 4 days ago86% |
BollingerBands ODDS (%) | 3 days ago80% | 3 days ago90% |
Aroon ODDS (%) | N/A | N/A |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RSESX | 16.61 | 0.18 | +1.10% |
Russell Inv US Strategic Equity S | |||
HSLIX | 44.72 | 0.40 | +0.90% |
Hartford Small Cap Growth I | |||
VBIAX | 50.33 | 0.38 | +0.76% |
Vanguard Balanced Index Adm | |||
GFGEX | 12.76 | -0.90 | -6.58% |
Guardian Fundamental Glb Eq instl | |||
JCAVX | 9.07 | -1.01 | -10.01% |
JHFunds2 Capital Appreciation Value NAV |
A.I.dvisor indicates that over the last year, IBB has been loosely correlated with TECH. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if IBB jumps, then TECH could also see price increases.
Ticker / NAME | Correlation To IBB | 1D Price Change % | ||
---|---|---|---|---|
IBB | 100% | +1.16% | ||
TECH - IBB | 65% Loosely correlated | +2.49% | ||
NTLA - IBB | 65% Loosely correlated | +0.83% | ||
CRSP - IBB | 65% Loosely correlated | +0.83% | ||
BEAM - IBB | 64% Loosely correlated | +8.04% | ||
DNLI - IBB | 63% Loosely correlated | -0.19% | ||
More |